Back to top
more

Johnson & Johnson (JNJ)

(Real Time Quote from BATS)

$160.28 USD

160.28
158,319

+0.59 (0.37%)

Updated Oct 9, 2024 09:50 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 13% (33 out of 252)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

J&J (JNJ) Q1 Earnings & Sales Top, 2023 View Up, Stock Rises

by Zacks Equity Research

J&J (JNJ) beats estimates for first-quarter earnings and sales. It raises full-year sales and earnings guidance.

Mark Vickery headshot

Housing Data Muted but Decent; JNJ and BAC Beat on Q1 Earnings

by Mark Vickery

Fresh Q1 earnings reports from major household firms join housing data from last month ahead of today's open.

Johnson & Johnson (JNJ) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Johnson & Johnson (JNJ) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 6.77% and 5.01%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Mark Vickery headshot

Q1 Earnings Season Kicks Off Better than Expected

by Mark Vickery

We've got a long way to go, but some key regional banks have already reported and offered some relief to market participants.

John Blank headshot

Will Any Banks Show Signs of Stress? Global Week Ahead

by John Blank

In terms of macro data, the first snapshot of business activity in April (the PMIs) could provide a sense of how much pain the turmoil in the banking sector has inflicted on the world economy.

Will J&J (JNJ) Pharma Unit Outperform Market & Drive Q1 Results?

by Zacks Equity Research

In J&J's (JNJ) Pharma segment, its oncology drug, Darzalex as well as a psoriasis treatment, Stelara is likely to have driven sales growth in the first quarter

Lilly's (LLY) Ulcerative Colitis Candidate Gets CRL from FDA

by Zacks Equity Research

The FDA rejects Eli Lilly's (LLY) regulatory filing seeking approval for mirikizumab to treat ulcerative colitis indication, citing issues related to the drug's proposed manufacturing.

J&J (JNJ) to Initiate Q1 Earnings Season for Pharma Sector

by Zacks Equity Research

Growth in J&J's (JNJ) Pharma unit is expected to have been driven by drugs like Darzalex and Stelara. In the MedTech segment, continued recovery in worldwide procedure volume should drive sales.

Sweta Killa headshot

Will Q1 Earnings Fuel a Rally in Dow ETF?

by Sweta Killa

As the index is closely tied to the cyclical sectors, the banking turmoil hit hard the Dow last month. Recession fears have added to the woes.

Is Vanguard Dividend Appreciation ETF (VIG) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for VIG

Analysts Estimate Johnson & Johnson (JNJ) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Johnson & Johnson (JNJ) closed at $164.32, marking a -0.5% move from the previous day.

AbbVie (ABBV), J&J to Withdraw 2 Blood Cancer Nods for Imbruvica

by Zacks Equity Research

AbbVie (ABBV)/J&J's (JNJ) decision to withdraw the FDA's accelerated approval for Imbruvica in two blood cancer treatments is based on confirmatory studies data that do not support full approval.

Yashwardhan Jain headshot

3 Sector ETFs to Play as Recession Fears Are on the Rise

by Yashwardhan Jain

With recession fears on the rise, look into some sectors that can shield from market volatility.

Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know

by Zacks Equity Research

Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

The Zacks Analyst Blog Highlights J&J, AstraZeneca, Merck, Seagen and Pfizer

by Zacks Equity Research

J&J, AstraZeneca, Merck, Seagen and Pfizer are part of the Zacks Top Analyst Blog.

Kinjel Shah headshot

Pharma Stock Roundup: J&J's $8.9B Offer for Talc Litigation Settlement & Other Updates

by Kinjel Shah

J&J (JNJ) offers a $8.9 billion settlement to resolve its talc lawsuits. FDA approves Merck's (MRK) Keytruda plus Seagen's Padcev for a bladder cancer indication.

Company News for Apr 6, 2023

by Zacks Equity Research

Companies in The News Are: CAG,FDX,AI,JNJ

Johnson & Johnson (JNJ) Soars 4.5%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Johnson & Johnson (JNJ) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

J&J (JNJ) Offers $8.9B Settlement for Talc Cancer Lawsuits

by Zacks Equity Research

To completely resolve its cosmetic talc litigation, J&J (JNJ) offers a settlement amount of $8.9 billion payable over a period of 25 years.

Company News for Apr 5, 2023

by Zacks Equity Research

Companies In The News Are: F, JNJ, GGB, AMC.

Should Vanguard Value ETF (VTV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for VTV

Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Johnson & Johnson (JNJ) closed the most recent trading day at $158.49, moving +1.05% from the previous trading session.

Merck (MRK), Seagen Drug Combo Gets FDA Nod for Bladder Cancer

by Zacks Equity Research

The combination of Merck's (MRK) Keytruda and Seagen's (SGEN) Padcev is the first approved immunotherapy and an antibody-drug conjugate for locally advanced or metastatic urothelial carcinoma.